您好,欢迎您

【2024 ESMO BC】前瞻:聚焦乳腺癌创新研究,共襄全球学术盛宴

04月19日
编译:肿瘤资讯
来源:肿瘤资讯

2024年欧洲肿瘤内科学会乳腺癌年会(2024 ESMO BREAST CANCER Annual Congress)将于5月15日至17日(CEST)在德国柏林会展中心举行。本次大会涵盖转化研究、新药物开发、分子与功能性诊断、生物标志物的应用、前沿科技的研究,以及患者护理等关键主题。大会将汇聚世界各地的顶尖专家,共同探讨和交流最新的研究成果和临床进展。【肿瘤资讯】整理了口头报告研究题目信息,提前为您揭晓大会的精彩内容。

优选论文专场1
Proffered Paper session 1

专场时间:5月15日 16:45 - 17:55

专场地点:Berlin Hall

专场主席:Erika P. Hamilton (Nashville, United States of America);Masakazu Toi (Bunkyo-ku, Japan)

 

摘要号:179O

中文标题:国际 II 期 DOLAF 试验:奥拉帕利、度伐利尤单抗和氟维司群联合治疗携带同源重组修复 (HRR) 缺陷或微卫星不稳定性 (MSI) 的ER+/HER2-晚期乳腺癌

英文标题:Combination of olaparib, durvalumab and fulvestrant in patients with advanced ER-positive, HER2-negative breast cancer harboring homologous recombination repair (HRR) deficiency or microsatellite instability (MSI): results of the international phase II DOLAF trial.

讲者:Séverine Guiu (Montpellier, Cedex 5, France) 

摘要号:180O

中文标题:IMpassion132:化疗±阿替利珠单抗治疗早期复发、不可切除的局晚期或转移性三阴性乳腺癌 (aTNBC) 的双盲、随机、3期试验

英文标题:IMpassion132 double-blind randomised phase 3 trial of chemotherapy (CT) ± atezolizumab (atezo) for early-relapsing unresectable locally advanced or metastatic triple-negative breast cancer (aTNBC)

讲者:Rebecca A. Dent (Singapore, Singapore)


摘要号:181O

中文标题:MORPHEUS-pan BC:一项针对局部晚期/转移性乳腺癌(LA/mBC)患者的多种治疗方案的Ib/II期研究,阿替利珠单抗+戈沙妥珠单抗(SG)组的中期分析(IA)

英文标题:Interim analysis (IA) of the atezolizumab (atezo) + sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A Phase Ib/II study of multiple treatment (tx) combinations in pts with locally advanced/metastatic BC (LA/mBC)

讲者:Peter Schmid (London, United Kingdom)

优选论文专场2
Proffered Paper session 2

专场时间:5月16日 16:45 - 18:15

专场地点:Berlin Hall

专场主席:Suzette Delaloge (Villejuif, Cedex, France)

摘要号:LBA2

中文标题:TROPION-Breast01研究的额外安全性分析:Datopotamab deruxtecan(Dato-DXd) vs 化疗用于既往经治、无法手术/转移性HR+/HER2-乳腺癌

英文标题:Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in pretreated, inoperable / metastatic HR+/HER2- breast cancer (BC): Additional safety analysis from TROPION-Breast01 

讲者:Komal Jhaveri (New York, United States of America)


摘要号:266O

中文标题:辅助生殖技术在年轻BRCA携带者乳腺癌后妊娠中的安全性:国际队列研究的结果

英文标题:Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: results from an international cohort study

讲者:Matteo Lambertini (Genova, Italy)

摘要号:109O

中文标题:SOFT和TEXT III期研究中绝经前浸润性小叶癌(ILC)的辅助内分泌治疗结局

英文标题:Adjuvant Endocrine Therapy for Premenopausal Invasive Lobular Carcinoma (ILC): Results from SOFT and TEXT phase III studies

讲者:Otto Metzger (Boston, United States of America)

简短口头报告专场1
Mini Oral session 1

专场时间:5月16日 08:30 - 10:00

专场地点:Munich Hall

专场主席:Peter A. Fasching (Erlangen, Germany);Thomas Bachelot (Lyon, France);Cristina Saura Manich (Barcelona, Spain)

摘要号:LBA3

中文标题:ipatasertib联合曲妥珠单抗和帕妥珠单抗 (HP) 双重抗HER2治疗PIK3CA突变HER2+晚期乳腺癌——来自Ib 期SOLTI-1507 IPATHER研究的主要结果

英文标题:SOLTI-1507 IPATHER: Primary results of the phase Ib study of ipatasertib (IPAT) and dual anti-HER2 therapy with trastuzumab and pertuzumab (HP) in patients (pts) with PIK3CA mutant (mut) HER2+ advanced breast cancer (ABC) 

讲者:Ana Mafalda Antunes De Melo e Oliveira (Barcelona, Spain)

 

摘要号:182MO

中文标题:T-DXd与医生选择治疗(TPC)在T-DM1经治的HER2+转移性乳腺癌患者中的比较:随机III期DESTINY-Breast 02研究的更新总生存期(OS)结果

英文标题:Trastuzumab deruxtecan (T-DXd) vs Treatment of Physician’s Choice (TPC) in Patients (pts) With HER2+ Metastatic Breast Cancer (mBC) Previously Treated With Trastuzumab Emtansine (T-DM1): Updated Overall Survival (OS) Results of the Randomized, Phase 3 DESTINY-Breast (DB-)02 Study

讲者:Sung-Bae Kim (Seoul, Korea, Republic of)

 

摘要号:267MO

中文标题:从(1级)间质性肺疾病/非感染性肺炎 (ILD) 恢复后,T-DXd再治疗的汇总分析

英文标题:Pooled Analysis of Trastuzumab Deruxtecan (T-DXd) Retreatment (RTx) After Recovery From Grade (Gr) 1 Interstitial Lung Disease/Pneumonitis (ILD)

讲者:Hope S. Rugo (San Francisco, CA, United States of America)

 

摘要号:183MO

中文标题:Capivasertib 和氟维司群用于芳香化酶抑制剂耐药的HR+/HER2-晚期乳腺癌患者:CAPItello-291试验中的第二次无进展生存期 (PFS2) 和至首次后续化疗的时间 (TFSC)

英文标题:Capivasertib and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): second progression-free survival (PFS2) and time to first subsequent chemotherapy (TFSC) in the CAPItello-291 trial 

讲者:Hope S. Rugo (San Francisco, CA, United States of America)

 

摘要号:1MO

中文标题:HER2DX 检测和生存结局:2,031例 HER2 阳性乳腺癌患者的患者-个体水平荟萃分析

英文标题:HER2DX assay and survival outcomes: an individual-patient level meta-analysis of 2,031 patients with HER2-positive breast cancer

讲者:Guillermo Villacampa Javierre (Barcelona, Spain)

 

摘要号:2MO

中文标题:SERENA-2试验的探索性分析:camizestrant或氟维司群治疗ER+/HER2-转移性乳腺癌中,ESR1 突变人群的 ctDNA动力学分析

英文标题:Dynamics of ESR1 mutation (ESR1m) circulating tumour DNA (ctDNA) in patients (pts) with estrogen receptor (ER)+ HER2– metastatic breast cancer (mBC) receiving camizestrant or fulvestrant: Exploratory analyses from the SERENA-2 trial

讲者:Mafalda Oliveira (Barcelona, Spain)

 

摘要号:3MO

中文标题:monarchE研究:HR+/HER2-、淋巴结阳性、高风险早期乳腺癌患者BRCA1/2种系突变和不常见体细胞变异分析

英文标题:Analysis of germline BRCA1/2 mutations and uncommon somatic alterations from patients with HR+, HER2-, node-positive, high-risk early breast cancer enrolled in monarchE

讲者:Christine Desmedt (Leuven, Belgium)

 

摘要号:4MO  

中文标题:NeoPAL研究中新辅助来曲唑+哌柏西利与化疗的比较:一项转化分析

英文标题:Neoadjuvant letrozole and palbociclib versus chemotherapy in the NeoPAL study: a translational analysis

讲者:Paul H. Cottu (Paris, CEDEX 5, France)

简短口头报告专场2
Mini Oral session 2

专场时间:5月17日 08:30 - 10:05

专场地点:Hamburg Hall

专场主席:Elzbieta Senkus-Konefka (Gdansk, Poland);Matteo Lambertini (Genova, Italy);Yoon-Sim Yap (Singapore, Singapore)

摘要号:LBA1

中文标题:Denosumab 联合2种不同的白蛋白结合型紫杉醇方案作为原发性乳腺癌患者的新辅助治疗——GeparX 2 × 2随机临床试验的至事件时间分析

英文标题:Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer - Time to Event analysis from the GeparX 2 × 2 Randomized Clinical Trial

讲者:Sibylle Loibl (Neu-Isenburg, Germany)

 

摘要号:110MO

中文标题:他汀类药物的使用与早期乳腺癌生存率:一项使用模拟目标试验方法的基于丹麦人群的队列研究

英文标题:Statin use and early breast cancer survival: A Danish population-based cohort study using an emulated target trial approach

讲者:Karl S. Harborg (Aarhus, Denmark)

摘要号:111MO

中文标题:定制剂量密集方案vs标准辅助化疗治疗高危早期乳腺癌:随机3期 PANTHER 试验中随访10年后的疗效结局和关键亚组分析

英文标题:Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: Efficacy outcomes and key subgroups after 10 years of follow-up in the randomized phase 3 PANTHER trial

讲者:Theodoros Foukakis (Stockholm, Sweden)

 

摘要号:268MO

中文标题:阴道雌激素治疗早期乳腺癌的安全性:一项基于全国人群的目标试验模拟

英文标题:Safety of vaginal estrogen therapy after early-stage breast cancer: a nationwide population-based target trial emulation

讲者:Elise Dumas (Paris, France)

 

摘要号:269MO  

中文标题:运动对转移性乳腺癌女性性健康和乳腺癌特异性症状负担的影响:国际多中心随机PREFERABLE-EFFECT试验的结果

英文标题:The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer: Results of the multinational randomized PREFERABLE-EFFECT trial

讲者:Martina E. Schmidt (Heidelberg, Germany)

 

摘要号:270MO

中文标题:评估乳腺癌患者生活质量的EORTC问卷的更新 - EORTC QLQ-BR42验证研究的IV期结果 

英文标题:An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients – Results of the validation study Phase IV EORTC QLQ-BR42

讲者:Vesna Bjelic-Radisic (Wuppertal, Germany)

 

摘要号:112MO

中文标题:CARABELA(GEICAM/2019-01) 试验:12个月的阿贝西利联合来曲唑治疗vs化疗新辅助治疗HR+/HER2-高度增殖 (Ki67≥20%) 乳腺癌

英文标题:Neoadjuvant study of 12 months of Abemaciclib plus Letrozole vs. Chemotherapy in HR+/HER2─ highly proliferative (Ki67≥20%) breast cancer: CARABELA (GEICAM/2019-01) Trial

讲者:Miguel Martin Jimenez (Madrid, Spain)

 

摘要号:184MO

中文标题:首创、下一代 CDK4 选择性抑制剂 PF-07220060 联合内分泌治疗用于CDK4/6 抑制剂经治的HR+/HER2-转移性乳腺癌:首次I/2a期人体研究的安全性和疗效数据更新

英文标题:First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 in combination with endocrine therapy (ET) in patients (pts) with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors (CDK4/6i): safety and efficacy update

讲者:Timothy Anthony Yap (Houston, Surrey, United States of America)

 

摘要号:113MO

中文标题:NATALEE研究更新:瑞波西利+非甾体芳香酶抑制剂(NSAI)在HR+/HER2-早期乳腺癌患者中的安全性和治疗持续时间

英文标题:NATALEE update: Safety and treatment (tx) duration of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC)

讲者:Carlos H. Barrios (Porto Alegre, Brazil)

5月15日会议日程

P5C9XQrNjnzoV8ROj2abc6jlylvOUy7E.png

5月16日会议日程

6C2QyZjHE03MX325uYIEC97TFvtpXb1X.png

5月17日会议日程

a0uHtAgQX5F50r7JKpLDq4C8IEJ8uW40.png

参考文献

https://cslide.ctimeetingtech.com/breast2024/attendee/confcal/session

责任编辑:肿瘤资讯-Jina
排版编辑:肿瘤资讯-张薪媛


版权声明

本文专供医学专业人士参考,未经著作人许可,不可出版发行。同时,欢迎个人转发分享,其他任何媒体、网站如需转载或引用本网版权所有内容,须获得授权,且在醒目位置处注明“转自:良医汇-肿瘤医生APP”。

BpRF22R6F7pYpwLiRWtZ4F7hXREcEJ5g.png

患者指南系列丛书,点我领取>>
查看详情

评论
04月23日
马利平
河南省肿瘤医院 | 放疗科
乳腺癌发病率还是前三位,对女性的威胁还是非常大
04月22日
雷昕奕
永州市中心医院 | 胃肠外科
共享全球盛宴。
04月20日
万军鸽
叶县人民医院 | 血液肿瘤科
聚焦乳腺癌创新研究,共襄全球学术盛宴